A detailed history of Ameriprise Financial Inc transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 61,516 shares of ITOS stock, worth $520,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,516
Previous 79,469 22.59%
Holding current value
$520,425
Previous $1.18 Million 46.73%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.09 - $17.97 $181,145 - $322,615
-17,953 Reduced 22.59%
61,516 $628,000
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $7,076 - $12,391
685 Added 0.87%
79,469 $1.18 Million
Q1 2024

May 15, 2024

BUY
$9.89 - $13.64 $59,972 - $82,712
6,064 Added 8.34%
78,784 $1.07 Million
Q4 2023

Feb 14, 2024

SELL
$8.57 - $11.06 $518,476 - $669,118
-60,499 Reduced 45.41%
72,720 $796,000
Q3 2023

Nov 14, 2023

SELL
$10.95 - $14.6 $2,354 - $3,139
-215 Reduced 0.16%
133,219 $1.46 Million
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $67,313 - $93,968
-5,206 Reduced 3.76%
133,434 $1.77 Million
Q1 2023

May 15, 2023

BUY
$13.02 - $22.62 $216,822 - $376,690
16,653 Added 13.65%
138,640 $1.89 Million
Q4 2022

Feb 14, 2023

SELL
$17.77 - $21.6 $3.13 Million - $3.81 Million
-176,346 Reduced 59.11%
121,987 $2.38 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $3.79 Million - $5.55 Million
203,749 Added 215.42%
298,333 $5.68 Million
Q2 2022

Aug 15, 2022

BUY
$16.57 - $35.1 $87,572 - $185,503
5,285 Added 5.92%
94,584 $1.95 Million
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $2.85 Million - $4.24 Million
89,299 New
89,299 $2.87 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $301M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.